Literature DB >> 33216694

Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March-July 2020.

Harvey W Kaufman1, Zhen Chen1, William A Meyer1, Jay G Wohlgemuth1.   

Abstract

Serologic tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) provide information on past infection and immune response. To better understand the persistence of immune response and the proportion of the population who can develop one, the authors assessed patterns of immunoglobulin G (IgG) positivity over time in individuals tested for SARS-CoV-2 RNA or IgG at a large national reference laboratory. More than 2.4 million SARS-CoV-2 IgG serology (initiated April 21, 2020) and 6.6 million nucleic acid amplification testing (NAAT) (initiated March 9, 2020) results on persons from across the United States as of July 10, 2020 were analyzed. Additional IgG serology results through August 11, 2020 were used for one household analysis. SARS-CoV-2 IgG positivity was observed in 91% (19,434/21,452) of individuals tested after a positive NAAT result and in 10% (7,831/80,968) after a negative NAAT result. Factors associated with seropositivity include age, region of patient residence, and interval between NAAT and IgG serology. The probability of persistent IgG seropositivity declined from 98.6% after 1 week to 74.3% after 2 months, less so in individuals ages ≥55 years than in younger groups. Specimens within 2 days from pairs of same-household members showed 92% IgG antibody concordance. Household adults were more frequently IgG positive prior to household children testing positive (36% versus 8%). IgG serology testing can identify an immune response to SARS-CoV-2 that varies based on age, sex, and duration since exposure. Loss of detectable IgG seropositivity occurs, in some patients, over weeks or months. Adults may be infecting household children.

Entities:  

Keywords:  COVID-19; SARS-CoV-2

Year:  2020        PMID: 33216694     DOI: 10.1089/pop.2020.0256

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  7 in total

1.  Rapid repeat infection of SARS-CoV-2 by two highly distinct delta-lineage viruses.

Authors:  Andrew J Gorzalski; Christina Boyles; Victoria Sepcic; Subhash Verma; Joel Sevinsky; Kevin Libuit; Stephanie Van Hooser; Mark W Pandori
Journal:  Diagn Microbiol Infect Dis       Date:  2022-06-22       Impact factor: 2.983

2.  Time-dependent decay of detectable antibodies against SARS-CoV-2: A comparison of ELISA with two batches of a lateral-flow test.

Authors:  Mariangela F Silveira; Marilia A Mesenburg; Odir A Dellagostin; Natasha R de Oliveira; Mara Ac Maia; Francisco D Santos; André Vale; Ana M B Menezes; Gabriel D Victora; Cesar G Victora; Aluisio Jd Barros; Luis Paulo Vidaletti; Fernando P Hartwig; Fernando C Barros; Pedro C Hallal; Bernardo L Horta
Journal:  Braz J Infect Dis       Date:  2021-08-05       Impact factor: 3.257

3.  Impact of both socioeconomic level and occupation on antibody prevalence to SARS-CoV-2 in an Egyptian cohort: The first episode.

Authors:  Mahmoud M Bahgat; Rola Nadeem; Mohamed H Nasraa; Mona A-E Awad; Solaf Kamel; Dina N Abd-Elshafy
Journal:  J Med Virol       Date:  2021-02-19       Impact factor: 20.693

Review 4.  The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries.

Authors:  Carlos E Dos Santos Ferreira; Hector Gómez-Dantés; Nancy C Junqueira Bellei; Eduardo López; Katya A Nogales Crespo; Miguel O'Ryan; Julieta Villegas
Journal:  Viruses       Date:  2021-11-29       Impact factor: 5.048

5.  Protective SARS-CoV-2 Antibody Response in Children With Inflammatory Bowel Disease.

Authors:  Luca Bosa; Costanza Di Chiara; Paola Gaio; Chiara Cosma; Andrea Padoan; Sandra Cozzani; Giorgio Perilongo; Mario Plebani; Carlo Giaquinto; Daniele Donà; Mara Cananzi
Journal:  Front Pediatr       Date:  2022-02-10       Impact factor: 3.418

6.  Should pregnant women be screened for SARS-CoV-2 infection? A prospective multicenter cohort study.

Authors:  Enav Yefet; Manal Massalha; Adi Alter; Amit Gal Harnik; Sally Hosari Mahamed; Lia Novick; Malak Wattad; Jawad Sakas; Shira Baram; Amir Weiss; Rula Iskander; Avi Peretz; Orit Rozenberg; Johnny S Younis; Yuri Perlitz; Zohar Nachum
Journal:  Int J Gynaecol Obstet       Date:  2022-07-16       Impact factor: 4.447

7.  SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.

Authors:  Niamh Allen; Melissa Brady; Antonio Isidro Carrion Martin; Lisa Domegan; Cathal Walsh; Elaine Houlihan; Colm Kerr; Lorraine Doherty; Joanne King; Martina Doheny; Damian Griffin; Maria Molloy; Jean Dunne; Vivion Crowley; Philip Holmes; Evan Keogh; Sean Naughton; Martina Kelly; Fiona O'Rourke; Yvonne Lynagh; Brendan Crowley; Cillian de Gascun; Paul Holder; Colm Bergin; Catherine Fleming; Una Ni Riain; Niall Conlon
Journal:  Microbiol Spectr       Date:  2021-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.